ReviewActa haematologica2021
G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?
Review in Acta haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?Frontiers in immunologyPooled it
- Post-COVID-19 Neutropenia in an Infant With Thalassemia Minor: Case Report.Clinical case reports · 2025Article
- Review
- Stress-induced eosinophil activation contributes to postoperative morbidity and mortality after lung resection.Science translational medicine · 2024Article
- Multi-cohort study on cytokine and chemokine profiles in the progression of COVID-19.Scientific reports · 2024Article
- Dynamics of cytokine and antibody responses in community versus hospital SARS-CoV-2 infections.Frontiers in immunology · 2024Article
- Aggravated pneumonia and diabetes in SARS-CoV-2 infected diabetic mice.Emerging microbes & infections · 2023Article
- Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation.International journal of molecular sciences · 2023Article
- Changes in chemokine and growth factor levels may be useful biomarkers for monitoring disease severity in COVID-19 patients; a pilot study.Frontiers in immunology · 2023Article
- Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients.International journal of molecular sciences · 2022Article
- Dilemma of Tocilizumab therapy for a patient with critical COVID-19 disease and neutropenia: Case report and review of the literature.Clinical case reports · 2022Article
- Unraveling the potential of endothelial progenitor cells as a treatment following ischemic stroke.Frontiers in neurology · 2022Review
- Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders.Frontiers in immunology · 2022Review
- Pancytopenia and Profound Neutropenia as a Sequela of Severe SARS-CoV-2 Infection (COVID-19) With Concern for Bone Marrow Involvement.Open forum infectious diseases · 2021Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.